Lilly And China's Hisun Complete Technology Transfer For Antibiotic Capreomycin For TB
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Eli Lilly and Chinese active pharmaceutical ingredient provider Hisun recently announced the completion of a technology transfer under which Lilly transferred technology to Hisun to produce finished products and API of its tuberculosis drug capreomycin